Viatris Inc
VTRSAPI behind this page
VTRS Q4 2025 request
Playground key active
/api/financials?ticker=VTRS&year=2025&quarter=4
Pick an endpoint and run the request.Income Statement
| Metric | Q4 2025 | Q4 2024 | YoY |
|---|---|---|---|
| Revenue | 3,690.7 | 3,515.4 | +5.0% |
Show Product Lines breakouts |
|||
| Amitiza ® | 42.4 | 41.1 | +3.2% |
| Brands | 2,345.8 | 2,165.9 | +8.3% |
| Brands · Developed Markets | 1,188.7 | 1,101.4 | +7.9% |
| Brands · Emerging Markets | 430.9 | 372.3 | +15.7% |
| Brands · Greater China | 570.2 | 519.8 | +9.7% |
| Brands · JANZ | 156 | 172.4 | -9.5% |
| Celebrex ® | 66.2 | 67.1 | -1.3% |
| Creon ® | 98.9 | 90.4 | +9.4% |
| Dymista ® | 38.6 | 41.3 | -6.5% |
| Effexor ® | 68.1 | 64.5 | +5.6% |
| EpiPen® Auto-Injectors | 79 | 73.1 | +8.1% |
| Generics | 1,344.9 | 1,349.5 | -0.3% |
| Generics · Developed Markets | 1,058.7 | 1,044.7 | +1.3% |
| Generics · Emerging Markets | 133.8 | 140.7 | -4.9% |
| Generics · Greater China | 2.7 | 2 | +35.0% |
| Generics · JANZ | 149.7 | 162.1 | -7.6% |
| Influvac ® | 63.6 | 52.7 | +20.7% |
| Lipitor ® | 377.3 | 355.9 | +6.0% |
| Lyrica ® | 119.8 | 127 | -5.7% |
| Norvasc ® | 175.2 | 166.2 | +5.4% |
| Viagra ® | 104.2 | 88.6 | +17.6% |
| Xalabrands | 42 | 37.1 | +13.2% |
| Xanax ® | 39.5 | 36.5 | +8.2% |
| Yupelri ® | 70.6 | 66.6 | +6.0% |
| Zoloft ® | 66.8 | 58.2 | +14.8% |
Show Business Segments breakouts |
|||
| Developed Markets · Operating Segments | 2,247.4 | 2,146.1 | +4.7% |
| Emerging Markets · Operating Segments | 564.7 | 513 | +10.1% |
| Greater China · Operating Segments | 572.9 | 521.8 | +9.8% |
| JANZ · Operating Segments | 305.7 | 334.5 | -8.6% |
| Other Revenue | 12.9 | 12.7 | +1.6% |
Show — breakouts |
|||
| Other Revenue | 10.9 | 9.4 | +16.0% |
| Other Revenue | 1.1 | 1 | +10.0% |
| Other Revenue | 0.9 | 1.8 | -50.0% |
| Revenue | 3,703.6 | 3,528.1 | +5.0% |
Show — breakouts |
|||
| Revenue | 2,258.3 | 2,155.5 | +4.8% |
| Revenue | -4,076.2 | -4,545.5 | +10.3% |
| Revenue | -3,961.3 | -4,638.1 | +14.6% |
| Revenue | 306.6 | 336.3 | -8.8% |
| Cost of Revenue | 2,555.7 | 2,313.1 | +10.5% |
| Gross Profit | 1,147.9 | 1,215 | -5.5% |
| Selling, General & Administrative | 1,030.7 | 1,046.7 | -1.5% |
| Goodwill Impairment Loss | 0 | 0 | — |
| Gain Loss Related To Litigation Settlement | -3.1 | 111.6 | -102.8% |
Show Consolidation Items breakouts |
|||
| Material Reconciling Items | -3.1 | 111.6 | -102.8% |
| Operating Expenses | 1,340.6 | 1,394.8 | -3.9% |
| Operating Income | -192.7 | -179.8 | -7.2% |
| Interest Expense | 119.6 | 120.2 | -0.5% |
| Other Non-Operating Income (Expense) | 30.7 | 226.5 | -86.4% |
| Income Before Taxes | -343 | -526.5 | +34.9% |
| Income Tax Expense (Benefit) | -2.9 | -10 | +71.0% |
| EPS (Basic) | -0.3 | -0.43 | +30.2% |
| EPS (Diluted) | -0.3 | -0.43 | +30.2% |
| Research & Development (Q) | — | — | — |
Show Consolidation Items breakouts |
|||
| Material Reconciling Items | 274.7 | 206.5 | +33.0% |
| Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax (Q) | — | — | — |
Show Derivative Risk breakouts |
|||
| Foreign Exchange Contract · Cash Flow Hedging | -0.9 | 44.2 | -102.0% |
| Foreign Exchange Contract · Net Investment Hedging | -3.5 | -0.2 | -1650.0% |
| Foreign Exchange Contract · Nondesignated | 9.5 | 231.5 | -95.9% |
| Interest Rate Swap · Cash Flow Hedging | -0.9 | -1 | +10.0% |
| Interest Rate Swap · Net Investment Hedging | 0.3 | 32.2 | -99.1% |
Balance Sheet
| Metric | Q4 2025 | Q4 2024 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 1,322.4 | 734.8 | +80.0% |
| Accounts Receivable | 3,031.3 | 3,221.3 | -5.9% |
Show Accounts Notes Loans And Financing Receivable By Receivable Type breakouts |
|||
| Variable Consideration | 2,268.6 | 2,536.4 | -10.6% |
| Variable Consideration · Chargebacks | 441.8 | 493.9 | -10.5% |
| Variable Consideration · Governmental rebate programs | 344.1 | 374.7 | -8.2% |
| Variable Consideration · Rebates, promotional programs and other sales allowances | 1,133.2 | 1,266.9 | -10.6% |
| Variable Consideration · Returns | 349.5 | 400.9 | -12.8% |
| Inventory | 3,999.2 | 3,854.1 | +3.8% |
| Prepaid Expenses & Other Current Assets | 1,436.3 | 1,710.5 | -16.0% |
| Total Current Assets | 9,789.2 | 9,520.7 | +2.8% |
| Non-Current Assets | |||
| Property, Plant & Equipment | 2,614 | 2,666.1 | -2.0% |
| Goodwill | 6,754.7 | 9,133.3 | -26.0% |
Show Business Segments breakouts |
|||
| Developed Markets | 5,024.5 | 6,752.9 | -25.6% |
| Emerging Markets | 797 | 1,163.8 | -31.5% |
| Greater China | 933.2 | 921.5 | +1.3% |
| Deferred Tax Assets | 1,061.2 | 753 | +40.9% |
| Other Non-Current Assets | 1,871.9 | 2,356.9 | -20.6% |
| Total Assets | 37,193.1 | 41,500.9 | -10.4% |
| Operating Lease Right-of-Use Assets | 271.3 | 253.1 | +7.2% |
| Intangible Assets | 14,396.1 | 16,256.7 | -11.4% |
Show Product Lines breakouts |
|||
| Brands · Developed Markets | 5,656 | 6,464.6 | -12.5% |
| Brands · Emerging Markets | 2,319.2 | 2,583.9 | -10.2% |
| Brands · Greater China | 4,355.3 | 4,779.7 | -8.9% |
| Brands · JANZ | 779.2 | 860.5 | -9.4% |
| Brands · Licensing Agreements | 13,109.7 | 14,688.7 | -10.7% |
| Generics · Developed Markets | 972 | 1,214.6 | -20.0% |
| Generics · Emerging Markets | 141.3 | 160.8 | -12.1% |
| Generics · Greater China | 6.1 | 8.7 | -29.9% |
| Generics · JANZ | 167 | 183.8 | -9.1% |
| Generics · Licensing Agreements | 1,286.4 | 1,567.9 | -18.0% |
Show Business Segments breakouts |
|||
| Developed Markets · Licensing Agreements | 6,628 | 7,679.2 | -13.7% |
| Emerging Markets · Licensing Agreements | 2,460.5 | 2,744.7 | -10.4% |
| Greater China · Licensing Agreements | 4,361.4 | 4,788.4 | -8.9% |
| JANZ · Licensing Agreements | 946.2 | 1,044.3 | -9.4% |
Show Finite Lived Intangible Assets By Major Class breakouts |
|||
| Licensing Agreements | 14,396.1 | 16,256.6 | -11.4% |
| Other Assets | |||
| Intangible Assets Net Excluding Goodwill | 15,102.1 | 17,070.9 | -11.5% |
| Current Liabilities | |||
| Accounts Payable Trade Current | 1,754.1 | 1,853.7 | -5.4% |
| Accrued Income Taxes Current | 124 | 192.7 | -35.7% |
| Current Portion of Long-Term Debt | 1,933.3 | 8.3 | +23192.8% |
| Other Liabilities Current | 3,282.9 | 3,724.7 | -11.9% |
| Total Current Liabilities | 7,094.3 | 5,779.4 | +22.8% |
| Debt Current | 1,929.9 | 0.6 | +321550.0% |
Show Debt Instrument breakouts |
|||
| 2026 Senior Notes (3.950%) · Senior Notes | 1,674.3 | — | — |
| Other Current Portion of Long-term Debt | 1 | 0.6 | +66.7% |
| YEN Term Loan | 255.2 | — | — |
| Non-Current Liabilities | |||
| Long-Term Debt | 12,480.6 | 14,038.9 | -11.1% |
| Deferred Tax Liabilities | 892 | 1,107.9 | -19.5% |
| Other Non-Current Liabilities | 2,014.9 | 1,939.2 | +3.9% |
| Total Liabilities | 22,481.8 | 22,865.4 | -1.7% |
| Long-Term Debt (Q) | — | — | — |
Show Debt Instrument breakouts |
|||
| 2027 Euro Senior Notes · Net Investment Hedging | 850 | — | — |
| 2027 Euro Senior Notes · Senior Notes | 1,011.5 | 899.4 | +12.5% |
| 2027 Senior Notes · Senior Notes | 758.6 | 764.2 | -0.7% |
| 2028 Euro Senior Notes · Senior Notes | 878.5 | 773.7 | +13.5% |
| 2028 Senior Notes · Net Investment Hedging | 750 | — | — |
| 2028 Senior Notes · Senior Notes | 749.5 | 749.3 | 0.0% |
| 2030 Senior Notes · Senior Notes | 1,488.8 | 1,497 | -0.5% |
| 2032 Euro Senior Notes · Net Investment Hedging | 1,250 | — | — |
| 2032 Euro Senior Notes · Senior Notes | 1,549.2 | 1,376.2 | +12.6% |
| 2040 Senior Notes · Senior Notes | 1,630.1 | 1,637.1 | -0.4% |
| 2043 Senior Notes (5.400%) · Senior Notes | 497.6 | 497.5 | 0.0% |
| 2046 Senior Notes (5.250%) · Senior Notes | 999.9 | 999.9 | 0.0% |
| 2048 Senior Notes · Senior Notes | 747.9 | 747.9 | 0.0% |
| 2050 Senior Notes · Senior Notes | 2,186.8 | 2,191.6 | -0.2% |
| Other Long Term Debt | 2.7 | 2.2 | +22.7% |
| YEN Term Loan · Net Investment Hedging | 40,000 | — | — |
Show Derivative Risk breakouts |
|||
| Net Investment Hedging | 2,850 | — | — |
| Operating Lease Liabilities | 178.1 | 179.3 | -0.7% |
| Stockholders' Equity | |||
| Common Stock | 12.5 | 12.3 | +1.6% |
| Additional Paid-In Capital | 18,801.3 | 18,921.6 | -0.6% |
| Retained Earnings | -388.3 | 3,418.8 | -111.4% |
| Accumulated Other Comprehensive Income | -2,707 | — | — |
| Stockholders Equity Parent Before Treasury Stock | 15,718.5 | 19,139.8 | -17.9% |
| Treasury Stock Value | 1,007.2 | 504.3 | +99.7% |
| Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 14,711.3 | 18,635.5 | -21.1% |
Show Equity Components breakouts |
|||
| Additional Paid In Capital | 18,801.3 | 18,921.6 | -0.6% |
| Common Stock | 12.5 | 12.3 | +1.6% |
| Retained Earnings | -388.3 | 3,418.8 | -111.4% |
| Treasury Stock Common | 1,007.2 | 504.3 | +99.7% |
| Total Liabilities & Equity | 37,193.1 | 41,500.9 | -10.4% |
| Total Stockholders' Equity (Q) | — | — | — |
Show Equity Components breakouts |
|||
| Accumulated Defined Benefit Plans Adjustment | 279.6 | 254.2 | +10.0% |
| Accumulated Gain Loss Net Cash Flow Hedge Parent | -3.1 | 32.3 | -109.6% |
| Accumulated Net Unrealized Investment Gain Loss | -0.4 | -1.2 | +66.7% |
| Accumulated Other Comprehensive Income | -2,707 | -3,212.9 | +15.7% |
| Accumulated Translation Adjustment | -3,088.2 | -3,990.8 | +22.6% |
| Aoci Derivative Qualifying As Hedge Excluded Component Parent | 105.1 | 492.6 | -78.7% |
Cash Flow Statement
| Metric | YTD Q4 2025 | YTD Q4 2024 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Depreciation & Amortization | 766.8 | 746.2 | +2.8% |
| Deferred Income Taxes | -248.2 | -248.9 | +0.3% |
| Changeinnoncashlitigationsettlementsnet | 4.9 | 28.9 | -83.0% |
| Gain Loss On Sale Of Business | 21.9 | 103.7 | -78.9% |
| Stock-Based Compensation | 49.4 | 32.3 | +52.9% |
| Payments To Acquire In Process Research And Development Other | 35.8 | 25 | +43.2% |
| Other Non-Cash Items | 133.5 | 157.3 | -15.1% |
| Change in Accounts Receivable | 271.9 | 300.5 | -9.5% |
| Change in Inventory | 15.8 | -35.6 | +144.4% |
| Increase Decrease In Accounts Payable Trade | 18.5 | 45.7 | -59.5% |
| Increase Decrease In Accrued Income Taxes Payable | 125.5 | -67.6 | +285.7% |
| Increase Decrease In Other Operating Capital Net | -39.9 | -88.3 | +54.8% |
| Net Cash from Operations | 815.8 | 482.7 | +69.0% |
| Investing Activities | |||
| Capital Expenditures | -196.5 | -140.4 | -40.0% |
| Other Investing Activities | -2.6 | -0.7 | -271.4% |
| Proceeds From Refund Of In Process Research And Development | -35.8 | -25 | -43.2% |
| Payments To Acquire Marketable Securities | -5.8 | -4.3 | -34.9% |
| Proceeds From Sale And Maturity Of Marketable Securities | 5.8 | 4.3 | +34.9% |
| Net Cash from Investing | -211.2 | -168.7 | -25.2% |
| Financing Activities | |||
| Payments Of Financing Costs | -0.2 | 0 | — |
| Share Repurchases | -85.1 | 0 | — |
| Tax Withholding for Share Compensation | 0.1 | 0 | — |
| Payments Of Merger Related Costs Financing Activities | 0 | 0 | — |
| Payments To Minority Shareholders | -138.2 | -143.3 | +3.6% |
| Proceeds From Issuance Of Common Stock | 0.6 | 0.6 | 0.0% |
| Proceeds From Payments For Other Financing Activities | -12 | 98.3 | -112.2% |
| Net Cash from Financing | -236.4 | -1,420.2 | +83.4% |
| Other Cash Flow | |||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | -23.7 | -37.8 | +37.3% |
| Net Change in Cash | 344.5 | -1,144 | +130.1% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 1,348 | 736.1 | +83.1% |
Values in millions USD. Source: SEC EDGAR 10-K filing.